Novo bets on Consumer Rx and five-blockbuster lineup amid investor pushback
At a London Capital Markets Day, Novo Nordisk outlined a Consumer Rx strategy and a plan to launch at least five multi-blockbusters by 2030, led by CagriSema (cagrilintide plus semaglutide) with assets like denecimig and zenagamtide; the push includes expanding Wegovy, broadening U.S. access, and boosting manufacturing, while cutting roughly 4,000 more jobs; investors sent the stock lower as they pressed for more detail on M&A and execution risk.